Daiken Biomedical Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 3, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	14,459	14,540	10,860	-	-
Market Cap Growth	58.01%	33.88%	-	-	-
Enterprise Value	9,143	9,496	9,874	-	-
Last Close Price	17.85	17.95	17.34	-	-
PE Ratio	38.10	43.03	101.90	-	-
PS Ratio	7.14	7.67	7.97	-	-
PB Ratio	2.62	2.67	8.31	-	-
P/TBV Ratio	2.62	2.67	8.33	-	-
P/FCF Ratio	48.30	53.42	215.06	-	-
P/OCF Ratio	48.24	53.34	209.86	-	-
EV/Sales Ratio	4.52	5.01	7.25	-	-
EV/EBITDA Ratio	28.20	32.17	64.48	-	-
EV/EBIT Ratio	29.16	32.95	66.31	-	-
EV/FCF Ratio	30.54	34.89	195.53	-	-
Debt / Equity Ratio	0.02	0.02	0.00	1.12	0.60
Debt / EBITDA Ratio	0.37	0.40	0.01	1.35	1.21
Debt / FCF Ratio	0.39	0.44	0.05	2.63	3.27
Net Debt / Equity Ratio	-0.96	-0.39	-0.87	-0.04	-0.47
Net Debt / EBITDA Ratio	-16.57	-7.17	-7.43	-0.05	-0.96
Net Debt / FCF Ratio	-17.76	-7.78	-22.52	-0.10	-2.59
Asset Turnover	0.52	0.51	1.19	1.87	-
Inventory Turnover	2.15	2.08	1.99	1.71	-
Quick Ratio	10.07	5.33	5.36	0.80	1.23
Current Ratio	10.93	13.12	6.56	1.64	2.17
Return on Equity (ROE)	10.01%	10.01%	13.71%	67.55%	-
Return on Assets (ROA)	5.04%	4.83%	8.15%	20.01%	-
Return on Invested Capital (ROIC)	14.06%	13.35%	55.95%	94.00%	77.31%
Return on Capital Employed (ROCE)	5.60%	5.30%	11.40%	68.80%	38.90%
Earnings Yield	2.33%	2.32%	0.98%	-	-
FCF Yield	2.07%	1.87%	0.46%	-	-
Dividend Yield	3.91%	3.89%	2.33%	-	-
Payout Ratio	174.73%	174.40%	2.89%	87.59%	-
Buyback Yield / Dilution	-51.92%	-52.12%	-95.20%	-44.34%	-
Total Shareholder Return	-47.99%	-48.23%	-92.87%	-44.34%	-